ruboxistaurin has been researched along with metoprolol in 1 studies
| Studies (ruboxistaurin) | Trials (ruboxistaurin) | Recent Studies (post-2010) (ruboxistaurin) | Studies (metoprolol) | Trials (metoprolol) | Recent Studies (post-2010) (metoprolol) |
|---|---|---|---|---|---|
| 203 | 29 | 56 | 5,821 | 1,743 | 1,304 |
| Protein | Taxonomy | ruboxistaurin (IC50) | metoprolol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.573 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.176 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4.87 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 4.87 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Houser, SR; Kranias, EG; Leitges, M; Liu, Q; Lorenz, JN; Macdonnell, SM; Molkentin, JD | 1 |
1 other study(ies) available for ruboxistaurin and metoprolol
| Article | Year |
|---|---|
Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Signaling; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Failure; Indoles; Maleimides; Metoprolol; Mice; Mice, Knockout; Myocardial Contraction; Myocardial Infarction; Myocardium; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Protein Kinase Inhibitors; Pulmonary Edema; Time Factors | 2009 |